Jaime Modiano

Oprichter bij ApopLogic Pharmaceuticals, Inc.

Consumer Services

Health Technology

Actieve functies van Jaime Modiano

Bedrijven	Functie	Begin	Einde
ApopLogic Pharmaceuticals, Inc. ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO.	Oprichter	01-08-2006	-

Bedrijven	Functie	Begin	Einde
University of Colorado Health Sciences Center	Corporate Officer/Principal	01-01-2007	01-01-2007
Texas A&M University	Corporate Officer/Principal	01-01-1999	01-01-1999
AMC Cancer Research Center	Corporate Officer/Principal	-	-

University of Pennsylvania	Doctorate Degree
El Colegio de México AC	Undergraduate Degree

Internationaal

Verenigde Staten	6
Mexico	2

Operationeel

Corporate Officer/Principal	3
Founder	1
Undergraduate Degree	1

Sectoraal

Consumer Services	5
Health Technology	2

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Bedrijven in privébezit	2
ApopLogic Pharmaceuticals, Inc. ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO.	Health Technology
AMC Cancer Research Center

Bedrijven in privébezit

Health Technology

AMC Cancer Research Center